Bibliographic Details
| Title: |
HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. |
| Authors: |
SHOGO NAKAMOTO, JUNICHIRO WATANABE, SHOICHIRO OHTANI, SATOSHI MORITA, MASAHIKO IKEDA |
| Source: |
In Vivo; May/Jun2020, Vol. 34 Issue 3, p1377-1386, 10p |
| Subject Terms: |
HER2 protein, BREAST cancer treatment, PACLITAXEL, BEVACIZUMAB, CANCER chemotherapy |
| Abstract: |
Background: The efficacy of paclitaxel and bevacizumab (PB) compared with other chemotherapies in patients with human epidermal growth factor receptor 2negative (HER2−) advanced breast cancer is unclear. Patients and Methods: We retrospectively investigated 301 patients with HER2− ABC who received first-line chemotherapy from January 2011 to December 2016. Results: We included 114 patients who received PB and 187 patients who received other chemotherapies. After propensity score matching, the PB group showed a significantly superior overall response rate (77.8% vs. 38.9%, p<0.0001) and median time to treatment failure (7.3 vs. 5.9 months, p=0.035). In subgroup analyses, PB improved the median overall survival of patients with pleural lesions or pulmonary lymphangiopathy (not reached vs. 18.9 months, p=0.037), and of patients with three or more metastatic sites without liver metastases, (48.0 vs. 27.3 months, p=0.015). Conclusion: Compared with conventional chemotherapy, PB improved the overall response rate and time to treatment failure in patients with HER2−advanced breast cancer and improved overall survival in some patient subgroups. [ABSTRACT FROM AUTHOR] |
|
Copyright of In Vivo is the property of International Institute of Anticancer Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
